AdAlta Limited

US biotech Ossianix Inc.’s CEO Frank Walsh is pleased with the progress of the company has made in cracking a problem that’s been “at the heart of neuroscience” for some time, the difficulty in gett

Sam Cobb, managing director and CEO of Australian biotech AdAlta Ltd. , talks to Scrip senior writer Lucie Ellis about the company’s recent public listing and clinical development plans for lead

Financings Third-quarter 2016 biopharma financing totaled $7.4 billion, a 54% increase over Q2’s $4.8 billion. Follow-on public offerings were again the lead financing vehicle, bringing in $3.36 billi

The immuno-oncology company Neon Therapeutics has appointed Richard Gaynor president of research and development. Gaynor will succeed interim chief scientific officer, Robert Tepper, a partner